We present the first reported case of an aortic valve replacement operation without blood transfusion in a 62-year-old Jehovah's Witness with dialysis-dependent chronic renal failure, severe anemia, severe aortic stenosis, and symptomatic angina with minimal exertion after an accident in which she suffered fractures of both her right arm and leg. She underwent successful valve replacement surgery after preoperative stabilization of her fractures and high-dose erythropoietin and iron supplement therapy preoperatively and postoperatively. The intraoperative blood conservation technique included a novel approach with a miniature cardiopulmonary bypass circuit and microplegia with limited hemodilution. High-risk valve surgery in patients who are Jehovah's Witnesses can be successful with a carefully planned multimodality blood conservation strategy.
C ardiac operations performed successfully with bloodless prime were reported as early as 1959 (1) . In 1962, Cooley et al reported the successful mitral valve repair in a Jehovah's Witness patient without using blood prime or transfusion (2) . Since then, many reports have confirmed that different cardiac procedures (including coronary bypass grafting, valve replacement or repair procedures, and even cardiac transplantation) without priming or transfusion can be done with an acceptable mortality and morbidity risk. With the development and availability of erythropoietin, better perioperative management of anemia without blood transfusion is now feasible.
Techniques of myocardial protection and the performance of the cardiopulmonary bypass system have also refined with time, thus improving the safety of most cardiac operations. However, patients with chronic renal failure on hemodialysis that have heart diseases requiring surgery present additional challenges to cardiac surgeons. They are usually anemic, commonly have platelet dysfunction, and are prone to have postoperative bleeding. Postoperatively, electrolyte and volume management in these patients can be problematic, and risks of pulmonary, cardiac, and neurological complications are high. Their reported operative mortality rate is significantly higher than that of the general population with normal renal function (3) (4) (5) (6) . Without the safety margin provided by perioperative blood and blood product replacement therapy, any cardiac operation in dialysis patients of this faith carries extreme risk.
Williams et al reported the first two cases of coronary artery bypass grafting in a dialysis-dependent Jehovah's Witness in 2004 (7) . The operations were performed off pump and thus avoided some of the potential problems uniquely associated with cardiopulmonary bypass. We had the opportunity to take care of a Jehovah's Witness patient with renal failure and severe aortic stenosis in 2004, and the following is the report of this unique case.
Case RepoRt
In May 2004, a 62-year-old Jehovah's Witness woman with a history of hypertension, diabetes mellitus, hyperlipidemia, and chronic renal failure was admitted to Baylor University Medical Center after fracturing her right radius and right tibia plateau following a fall. On admission, her weight was 55 kg; height, 155 cm; and body surface area, 1.54 m 2 . She had been on hemodialysis since 2001, and her usual hemoglobin and hematocrit were 12 g/dL and 36%, respectively, before the injury. She was receiving erythropoietin (Epogen) 10,000 units three times a week with her dialysis. The patient had a history of anemia and refused blood transfusion because of her religious beliefs.
During her admission evaluation, in addition to her bony injuries, she complained of chest pain and shortness of breath with minimal activity. Her hematocrit was 27%, and a holosystolic murmur was heard over her left anterior chest, radiating to the neck. A cardiologist performed a workup, which included an echocardiogram and right and left heart catheterization. She was found to have angina related to severe aortic stenosis with left ventricular hypertrophy. The aortic valve was heavily calcified, with a valve area of only 0.4 cm 2 and a transvalvular gradient of 85 mm Hg. Left ventricular function was normal, with an ejection fraction of 60%, and coronary artery anatomy was unremarkable except for a 50% left circumflex artery stenosis.
The patient's orthopaedic surgeon did not believe she would tolerate surgical repair of her injury at that time and elected to treat the fractures with splinting, casting, and traction. We aortic valve replacement in a dialysis-dependent Jehovah's Witness: successful use of a minicircuit, microplegia, and multimodality blood conservation technique were consulted to evaluate her for possible aortic valve replacement because of the persistent angina. After extensive discussion with the patient, her family, and all the involved physicians, we increased her erythropoietin dose to 20,000 units three times a week concurrently with ferrous sulfate 325 mg three times per day. Three weeks later, her hemoglobin was 12 g/dL, and her hematocrit was 39%; the operation was performed in June 2004.
The patient was premedicated with midazolam 5 mg, and a brachial arterial line and oximetric pulmonary artery catheter were inserted for monitoring of hemodynamic parameters. Endotracheal anesthesia was induced with low-dose propofol 1 mg/kg, fentanyl 1 mcg/kg, and rocuronium 1 mg/kg. Anesthesia was maintained with isoflurane 1% to 2% and additional fentanyl (2 mcg/kg). Electroencephalographic monitoring was instituted with a patient state analyzer (PSA 4000, Physiometrix, Lake Forest, IL) and maintained at 10 to 40 microvolts throughout the procedure.
A median sternotomy was utilized for surgical exposure. Heparin was given at a dose of 4 mg/kg prior to initiating cardiopulmonary bypass to keep the activated clotting time >400 seconds. A 21F arterial dispersion catheter (Edwards Lifesciences, Irvine, CA) inserted into the aortic arch and a 29F/37F dual-stage venous return catheter (Edwards Lifesciences) placed in the right atrium completed the extracorporeal cardiopulmonary bypass circuit. We used an automated System 1 heart-lung machine with a Delphin arterial centrifugal pump (Terumo Cardiovascular Systems, Inc, Ann Arbor, MI) attached to a ⅜-inch miniature X-coated polymer circuit with reduced prime volume and a 1.8-m 2 hollow fiber membrane oxygenator (Terumo Cardiovascular Systems, Inc). An in-line hemofilter (Terumo Cardiovascular Systems, Inc), a leukocyte-reducing arterial filter (Pall Medical, New York, NY), and a cardiotomy reservoir (Medtronic, Inc, Minneapolis, MN) were also used (Figure) . Additional intraoperative blood conservation strategies included rapid autologous priming prior to initiation of bypass, administration of desmopressin at 0.3 mcg/kg, and infusion of a total dose of 6 million units of aprotinin.
Myocardial protection was achieved using systemic cooling to 28°C, and autotransfusion was accomplished intraoperatively with the BRAT autotransfusion system (Cobe Cardiovascular, Inglewood, CO). Antegrade and retrograde cold blood potassium cardioplegia with added magnesium sulfate was delivered using the Quest MPS microplegia system (Quest Medical, Inc, Allen, TX) to reduce hemodilution and improve potassium and glucose control.
The calcified tricuspid aortic valve was removed intraoperatively and replaced with a 21 mm Mitroflow pericardial valve (Mitroflow Inc, Richmond, BC, Canada). No coronary bypass was done. At the conclusion of the operation, the patient was successfully weaned from extracorporeal circulation, and the heparin effect was then reversed with protamine sulfate at a dose of 1.3 mg per unit of heparin.
Total cardiopulmonary bypass time was 77 minutes; crossclamp time was 55 minutes (Table) . No inotropic agent was used perioperatively. The lowest hematocrit during bypass was 25%, and immediately postoperatively the hemoglobin was 11.9 g/dL and the hematocrit rose to 35%. An intraoperative transesophageal echocardiogram was used to evaluate ventricular function and valve function and to facilitate the de-air maneuver. Ventricular function was found to be normal with good prosthetic valve function and no perivalvular leak. The echocardiogram results showed that the peak gradient through the valve was 17 mm Hg, and the mean gradient was 7 mm Hg.
The patient was extubated 72 minutes postoperatively, was dialyzed, and was transferred to the intensive care unit the next day. She was continued on erythropoietin 10,000 units subcutaneously with her dialysis three times a week postoperatively. The patient was also maintained on aspirin 325 mg, atorvastatin 20 mg, and ferrous sulfate 324 mg daily, in addition to her routine renal and diabetic medications. Her fractures were managed by the orthopaedic surgery consultant, and physical therapy was started 2 days after the valve surgery. She was transferred to a rehabilitation facility 10 days later with a discharge hematocrit of 32%. This patient has since been seen at 1-and 6-month follow-up visits; she had normal valve function and no cardiac symptoms. Her right arm and leg fractures have completely healed, with full range of motion and strength.
DisCussion
Cardiac valve surgery in dialysis patients is rare. In one of the largest valve surgery series (over 8000 cases), as reported by the Cleveland Clinic (8), only 0.5% of the patients had dialysis-dependent chronic renal failure. The reported mortality rate associated with heart valve surgery in renal failure patients is about 10% to 15% (8) (9) (10) . No valve surgery has previously been reported in a Jehovah's Witness patient who was dialysis dependent (8, 11, 12) . This case was particularly challenging because of the patient's small size, anemia related to renal failure and traumatic injury, platelet dysfunction, and refusal of transfusion therapy. The successful outcome of this case was based on the careful perioperative planning and execution of a meticulous hemostatic surgical technique.
Intensive preoperative treatment with erythropoietin and an oral iron supplement has been shown to be effective in significantly increasing hemoglobin and hematocrit levels in cardiac surgery patients. This method is safe, cost effective, and well tolerated. Increasing red cell volume preoperatively provides a greater safety margin for a patient to prevent postoperative anemia. Intraoperative use of antifibrinolytic agents such as aprotinin has been shown to decrease blood loss, alleviate a systemic inflammatory reaction, and potentially improve neurological outcomes in cardiac surgery patients (13) . The possible deleterious effect of aprotinin on the kidney was not an issue since this patient was already dependent on hemodialysis. We also used desmopressin intraoperatively; this has been shown to decrease bleeding in patients with platelet dysfunctions associated with renal failure (14) .
The modification of the cardiopulmonary bypass technique used in this case was based on our cumulative operative experience with other Jehovah's Witness patients (15) . The principal objectives were to 1) minimize hemodilution, 2) decrease systemic inflammatory reactions associated with extracorporeal perfusion, and 3) prevent postoperative volume overload and hyperkalemia. Because this patient would not accept blood or blood product transfusion, minimizing hemodilution and preventing excessive blood loss during the operation were crucial. We utilized a miniaturized perfusion circuit coupled with a rapid autologous priming technique to reduce the priming volume requirement, thereby reducing hemodilution. The priming volume was reduced to 1200 cc from a typical 2500 cc. To further decrease hemodilution, we used a microplegia system that was able to deliver 1200 cc of blood cardioplegia with only 16 cc of crystalloid solution added. Intraoperatively, we also used ultrafiltration to reduce the blood volume once extracorporeal perfusion was terminated. This step was critical in an anuric renal failure patient to prevent postoperative volume overload.
Extracorporeal perfusion is known to increase complement activation and enhance systemic inflammatory mediator production, and the use of cardiopulmonary bypass is implicated in the adverse pulmonary and neurological complications associated with cardiac surgery (16, 17) . By using a miniaturized perfusion circuit with a bioactive coating system and continuous leukocyte filtration, we sought to decrease the blood-surface interface and lessen the extent of systemic inflammation so that potential postoperative complications would be reduced (18) .
The choice of replacement heart valves in renal failure patients has been controversial (8) (9) (10) . Accelerated calcification of bioprosthetic valves has been a concern due to the prevalence of secondary hyperparathyroidism among renal failure patients. Conversely, anticoagulation therapy required for patients with implanted mechanical heart valves has been associated with increased hemorrhage and thromboembolic complications. Recent registry data on patients with renal failure suggested that the average 3-year survival rate for these patients after heart valve surgery is only 50%. Considering the two valve options, this evidence negated the theoretical advantage of using the more durable mechanical valve in this group of high-risk patients (19) . We decided to choose the bioprosthetic valve with the best hemodynamic properties in this patient, who would not accept any transfusion, to minimize potential future hematological complications.
This multimodality approach may be effective in select highrisk patients who are candidates for cardiac surgery procedures. We believe its utilization should be considered if indicated.
